Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
Rhea-AI Summary
MindMaze Therapeutics (SIX:MMTX) completed a business combination with NeuroX on December 15, 2025, creating an integrated company combining precision digital neurotherapeutics, pharmacological assets, devices, data, and an AI platform to treat neurological disease.
The deal used a share exchange that issued 140,000,000 new ordinary shares, bringing total outstanding shares to 152,602,044 (excluding treasury shares). The newly issued shares are admitted to trading on the SIX Swiss Exchange and the company will trade under ticker MMTX effective immediately.
Positive
- Integrated platform unites digital therapeutics, drugs, devices, data and AI
- Shares admitted to trading on SIX under ticker MMTX on December 15, 2025
- Clinically validated neurotherapeutics emphasized as strategic foundation
Negative
- Large share issuance of 140,000,000 new shares increases outstanding to 152,602,044
Details
News Market Reaction – RLFTF
In the Dec 15 session, RLFTF declined 57.48%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- New NeuroX shares
- 140,000,000 shares
- Newly issued ordinary shares in share exchange
- Total shares outstanding
- 152,602,044 shares
- Post-transaction, excluding treasury shares
- Neurological disease prevalence
- 1 in 6 people
- Expected to develop a neurological disease
- Price change pre-news
- -2.8%
- Move in prior 24 hours before this announcement
- 52-week high
- 7.66
- Pre-news 52-week high for RLFTF
- 52-week low
- 2.25
- Pre-news 52-week low for RLFTF
- 200-day moving average
- 3.27
- Pre-news MA(200) for RLFTF
- Float shares
- 12,540,439 shares
- Shares float from risk context
Historical Context
-
Shareholders approved NeuroX business combination and name change.
-
Pipeline and cash runway update, plus pursuit of NeuroX combination.
-
Earlier publication date for 2025 half-year report.
-
Announced proposed business combination and valuation terms with NeuroX.
-
FDA declined QIDP for RLF-TD011; Orphan and Rare Pediatric maintained.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
business combination financial
ticker symbol technical
neurotherapeutics medical
ai-powered platform technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The newly combined entity now operates under the name MindMaze Therapeutics Holding SA.
The closing follows the signing of a definitive business combination agreement in October 2025 and subsequent shareholder approval at the Company's extraordinary general meeting in November. The transaction establishes a fully integrated company with a first-of-its-kind ecosystem, uniting precision digital neurotherapeutics, pharmacological treatments, cutting-edge devices, data, and an AI-powered platform, positioned to redefine neurological care and change patient lives.
"Neurological diseases are one of the leading causes of disability globally," said Olaf Blanke (MD), member of the Board of Directors, Professor of Neuroscience and Cognitive Neuroprosthetics at the Swiss Federal Institute of Technology (EPFL) and Adjunct Professor at the Department of Clinical Neurosciences at the University Hospital of Geneva. "The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease, making the need for effective, scalable solutions more urgent than ever. While neuro-rehabilitation requires intensive, repetitive training for functional recovery, traditional healthcare systems often fail to deliver adequate therapy, leaving millions of patients without optimal treatment. MindMaze Therapeutics seeks to address this gap by providing clinically proven neurotherapeutics to support their recovery journey, from hospital to rehab center to their home."
"Today begins a new chapter for MindMaze Therapeutics," commented Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics. "The company is founded on clinically validated innovation, and driven by a mission to transform neurological care, addressing a critical and persistent gap in motor and cognition restorations in neurological conditions. We are now focused on advancing our precision neurotherapeutics platform to deliver impact at scale. Relief's complementary capabilities and biopharmaceutical assets strengthen our growth strategy, supporting both drug-digital integration and expanding development opportunities."
MindMaze Therapeutics acquired NeuroX through a share exchange in which all outstanding shares of NeuroX were contributed by its former shareholders in exchange for 140,000,000 newly issued ordinary shares of the Company. These new shares will be admitted to trading and listing on the SIX Swiss Exchange today, in accordance with the approved prospectus and applicable regulations. Effective immediately, all listed ordinary shares of the Company will trade under the updated ticker symbol MMTX. Following the transaction, the total number of outstanding shares amounts to 152,602,044, excluding treasury shares.
ABOUT MINDMAZE THERAPEUTICS
MindMaze Therapeutics is a Swiss-based, commercial-stage company formed in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA (Relief) and NeuroX Group SA. The Company develops and commercializes first-of-its-kind digital treatments for neurological diseases and brain disorders. Built on an advanced brain technology platform integrating software, sensors, and telehealth, its solutions are deployed globally across clinics and home settings. MindMaze Therapeutics' clinically validated neurotherapeutics have demonstrated significant medico-economic outcomes across conditions such as stroke, Parkinson's disease, and at-risk aging. The Company continues to expand its R&D pipeline into adjacent neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer's disease.
The Company also manages Relief's preexisting portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker MMTX and quoted in the U.S. on OTCQB under RLFTF and RLFTY.
For more information, visit www.mindmazetherapeutics.com.
CONTACT
MindMaze Therapeutics Holding SA
Jeremy Meinen
Chief Financial Officer
ir@mindmaze.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company's ability to execute its strategy and secure sufficient resources to support its operations. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.